Calliditas Therapeutics AB (publ)
Built from real-time financials and updated daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a CALTX.ST research report →
Companywww.calliditas.se
Calliditas Therapeutics AB (publ), a clinical-stage biopharmaceutical company, focused on identifying, developing, and commercializing pharmaceuticals products for treatments in orphan indications with initial focus on renal and hepatic diseases. It offers Nefecon, an oral formulation of budesonide that is an immunosuppressant for the treatment of the autoimmune renal disease immunoglobulin A nephropathy. The company's lead product candidate is Setanaxib, a NOX inhibitor that is in Phase 2b/3 clinical trial for the treatment of primary biliary cholangitis; and in Phase 2 clinical trial for the treatment of squamous cell carcinoma of the head and neck cancer and idiopathic pulmonary fibrosis, as well as for type 1 diabetic kidney disease.
- CEO
- Renee Aguiar-Lucander
- IPO
- 2018
- Employees
- 222
- HQ
- Stockholm, SE
Price Chart
Valuation
- Market Cap
- $11.24B
- P/E
- -23.95
- P/S
- 9.31
- P/B
- 33.34
- EV/EBITDA
- -30.57
- Div Yield
- 0.00%
Profitability
- Gross Margin
- 93.62%
- Op Margin
- -31.85%
- Net Margin
- -38.63%
- ROE
- -84.68%
- ROIC
- -25.31%
Growth & Income
- Revenue
- $1.21B · 50.32%
- Net Income
- $-466,185,000 · -13.08%
- EPS
- $-8.69 · -11.70%
- Op Income
- $-384,397,000
- FCF YoY
- -42.56%
Performance & Tape
- 52W High
- $208.80
- 52W Low
- $80.80
- 50D MA
- $206.64
- 200D MA
- $157.74
- Beta
- 1.46
- Avg Volume
- 98.18K
Get TickerSpark's AI analysis on CALTX.ST
Pro members can request AI-generated analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →30-day money-back guarantee · cancel anytime
Our CALTX.ST Coverage
We haven't published any research on CALTX.ST yet
For a full analyst-grade research report — grades, price targets, full financials, chart analysis — generate one on demand.
Generate CALTX.ST Report →